NCT05376644View on ClinicalTrials.gov

Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

January 21, 2023

Conditions
Breast Cancer Female
Interventions
DRUG

99mTc-ADAPT6

One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.

DRUG

99mTc-DARPinG3

One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.

Trial Locations (1)

634005

Tomsk NRMC, Tomsk

All Listed Sponsors
collaborator

Uppsala University

OTHER

lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER